BRPI0814116A2 - Anticorpo monoclonal citotóxico anticâncer - Google Patents
Anticorpo monoclonal citotóxico anticâncerInfo
- Publication number
- BRPI0814116A2 BRPI0814116A2 BRPI0814116-9A2A BRPI0814116A BRPI0814116A2 BR PI0814116 A2 BRPI0814116 A2 BR PI0814116A2 BR PI0814116 A BRPI0814116 A BR PI0814116A BR PI0814116 A2 BRPI0814116 A2 BR PI0814116A2
- Authority
- BR
- Brazil
- Prior art keywords
- monoclonal antibody
- cytotoxic monoclonal
- cytotoxic
- antibody
- monoclonal
- Prior art date
Links
Classifications
-
- G01N33/5758—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94994707P | 2007-07-16 | 2007-07-16 | |
| PCT/CA2008/001288 WO2009009881A1 (en) | 2007-07-16 | 2008-07-14 | An anti-cancer cytotoxic monoclonal antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0814116A2 true BRPI0814116A2 (pt) | 2015-02-03 |
Family
ID=40259249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0814116-9A2A BRPI0814116A2 (pt) | 2007-07-16 | 2008-07-14 | Anticorpo monoclonal citotóxico anticâncer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20090022662A1 (pt) |
| EP (1) | EP2178918A1 (pt) |
| KR (1) | KR20100028643A (pt) |
| CN (1) | CN101687931A (pt) |
| AU (1) | AU2008278227A1 (pt) |
| BR (1) | BRPI0814116A2 (pt) |
| CA (1) | CA2692912A1 (pt) |
| TW (1) | TW200922619A (pt) |
| WO (1) | WO2009009881A1 (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2291406A4 (en) * | 2008-05-19 | 2012-12-12 | Takeda Pharmaceutical | Cytotoxic monoclonal antibody against cancer |
| US10259204B2 (en) | 2010-04-30 | 2019-04-16 | Columbia Insurance Company | Resilient flooring product and methods of making same |
| JP2011236733A (ja) | 2010-04-30 | 2011-11-24 | Shaw Industries Group Inc | 非ビニル弾性床製品およびその作製方法 |
| DE102018123994B4 (de) | 2018-09-28 | 2022-05-25 | Knorr-Bremse Systeme für Nutzfahrzeuge GmbH | Kontaktiervorrichtung zum federbaren Kontaktieren einer Platine mit einem Kontaktelement für eine Magnetspule oder einen Sensor für ein Fahrzeugsystem, Fahrzeugsystem mit einer Kontaktiervorrichtung und Verfahren zum Herstellen einer Kontaktiervorrichtung |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7442777B2 (en) * | 2000-11-29 | 2008-10-28 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| CA2471206A1 (en) * | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| US7399835B2 (en) * | 2004-02-26 | 2008-07-15 | Arius Research Inc. | Cancerous disease modifying antibodies |
| US7420041B2 (en) * | 2006-02-24 | 2008-09-02 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of TROP-2 |
-
2008
- 2008-07-14 BR BRPI0814116-9A2A patent/BRPI0814116A2/pt not_active Application Discontinuation
- 2008-07-14 KR KR1020107001037A patent/KR20100028643A/ko not_active Ceased
- 2008-07-14 AU AU2008278227A patent/AU2008278227A1/en not_active Abandoned
- 2008-07-14 WO PCT/CA2008/001288 patent/WO2009009881A1/en not_active Ceased
- 2008-07-14 CN CN200880024555A patent/CN101687931A/zh active Pending
- 2008-07-14 CA CA 2692912 patent/CA2692912A1/en not_active Withdrawn
- 2008-07-14 EP EP08783208A patent/EP2178918A1/en not_active Withdrawn
- 2008-07-14 US US12/172,645 patent/US20090022662A1/en not_active Abandoned
- 2008-07-16 TW TW097126915A patent/TW200922619A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW200922619A (en) | 2009-06-01 |
| AU2008278227A1 (en) | 2009-01-22 |
| EP2178918A1 (en) | 2010-04-28 |
| KR20100028643A (ko) | 2010-03-12 |
| CN101687931A (zh) | 2010-03-31 |
| US20090022662A1 (en) | 2009-01-22 |
| CA2692912A1 (en) | 2009-01-22 |
| WO2009009881A1 (en) | 2009-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2021027I1 (el) | Σκευασματα αντισωματων anti-cd20 | |
| CY2019004I1 (el) | Τροποποιημενα αντισωματα αντι-ιl-23ρ19 | |
| BRPI0814111A2 (pt) | Anticorpo monoclonal citotóxico anticâncer | |
| NO344963B1 (no) | Humanisert antistoff | |
| DK2066695T3 (da) | Anti-myostatin-antistoffer | |
| PL3059246T3 (pl) | Zmodyfikowany region stały przeciwciała | |
| EP2324359A4 (en) | MONOCLONAL ANTIBODY STRO-4 | |
| BRPI0814252A2 (pt) | Formulações de anticorpo | |
| DK2274012T3 (da) | Cytotoksisk immunoglobulin | |
| BRPI0907532A2 (pt) | Anticorpos anti-c5ar humanizados | |
| BRPI0819165A2 (pt) | Anticorpos anti-vegf | |
| EP2181121A4 (en) | CHIMÄRE ANTIGENE | |
| BRPI0807991A2 (pt) | Anticorpos anti-il-23r elaborados. | |
| BRPI0821777A2 (pt) | Anticorpos biespecíficos bivalentes | |
| DK2131860T3 (da) | Anti-sclerostin-antistoffer | |
| PT2195026E (pt) | Anticorpos anti-esclerostina | |
| ZA201000049B (en) | Monoclonal antibeta amyloid antibody | |
| FI20075278A0 (fi) | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet | |
| BRPI0809677A2 (pt) | Anticorpos anti-ige | |
| SMT201700083B (it) | Anticorpi monoclonali | |
| BRPI0907237A2 (pt) | Anticorpo anti-cldn6 | |
| HRP20171011T1 (hr) | ANTI-eMET ANTITIJELO | |
| BRPI0820819A2 (pt) | Formulação de anticorpos | |
| DK2059533T3 (da) | Multispecifikke antistoffer | |
| EP2211903A4 (en) | CLL-1 ANTIBODY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Ipc: G01N 33/574 (2006.01), A61K 47/68 (2017.01), A61K |